Fig. 2: Kaplan–Meier Estimates of Progression-free Survival and Overall survival according to ShallowHRDv2 or Mychoicetest in PAOLA-1 trial. | Oncogene

Fig. 2: Kaplan–Meier Estimates of Progression-free Survival and Overall survival according to ShallowHRDv2 or Mychoicetest in PAOLA-1 trial.

From: Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial

Fig. 2

Kaplan–Meier estimates of (A) PFS for PAOLA-1 patients according to homologous recombination status as determined by shallowHRDv2 or MyChoice and to the treatment arm. B OS for PAOLA-1 patients according to homologous recombination status as determined by shallowHRDv2 or MyChoice and to the treatment arm. C PFS according to homologous recombination status as determined by shallowHRDv2 and to the treatment arm for PAOLA-1 patients with non-contributive results by MyChoice. HR Hazard Ratio, PFS Progression Free Survival, OS Overall Survival.

Back to article page